Key result
Novel sandwich ELISA specifically detects CVB1 mature virions down to ~4 ng/mL.
A newly developed specific double-antibody sandwich ELISA enables accurate quantification of CVB1 mature virions, supporting optimization of virus purification and vaccine development.
May facilitate CVB1 vaccine manufacturing optimization; leaves open clinical translation and efficacy trials.
• The developed quantitative double-antibody sandwich ELISA supports the vaccine development, production, and quality control of CVB1 vaccine. • This method enables real-time monitoring of mature virion proportions during production, facilitating the optimization of production conditions. • Combining DAS-ELISA with density gradient centrifugation enables precise tracking of CVB1-M distribution, thereby guiding efficient purification. • The established DAS-ELISA offers rapid detection, low sample consumption, cost-effectiveness, and objective quantification.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied Coxsackievirus B1 infection. Double-antibody sandwich ELISA (DAS-ELISA) was evaluated on Detection specificity and limit of detection (LOD) for CVB1 mature virions. The developed double-antibody sandwich ELISA specifically detected Coxsackievirus B1 mature virions without cross-reactivity, demonstrating a limit of detection of 4.12 ng/mL for purified virions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: